Your browser doesn't support javascript.
Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong.
Chen, Lin-Lei; Abdullah, Syed Muhammad Umer; Chan, Wan-Mui; Chan, Brian Pui-Chun; Ip, Jonathan Daniel; Chu, Allen Wing-Ho; Lu, Lu; Zhang, Xiaojuan; Zhao, Yan; Chuang, Vivien Wai-Man; Au, Albert Ka-Wing; Cheng, Vincent Chi-Chung; Sridhar, Siddharth; Yuen, Kwok-Yung; Hung, Ivan Fan-Ngai; Chan, Kwok-Hung; To, Kelvin Kai-Wang.
  • Chen LL; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, The University of Hong Kong, Hong Kong SAR, China.
  • Abdullah SMU; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, The University of Hong Kong, Hong Kong SAR, China.
  • Chan WM; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, The University of Hong Kong, Hong Kong SAR, China.
  • Chan BP; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, The University of Hong Kong, Hong Kong SAR, China.
  • Ip JD; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, The University of Hong Kong, Hong Kong SAR, China.
  • Chu AW; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, The University of Hong Kong, Hong Kong SAR, China.
  • Lu L; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, The University of Hong Kong, Hong Kong SAR, China.
  • Zhang X; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, The University of Hong Kong, Hong Kong SAR, China.
  • Zhao Y; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, The University of Hong Kong, Hong Kong SAR, China.
  • Chuang VW; Quality and Safety Division, Hospital Authority, Hong Kong SAR, China.
  • Au AK; Centre for Health Protection, Department of Health, Hong Kong SAR, China.
  • Cheng VC; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, The University of Hong Kong, Hong Kong SAR, China.
  • Sridhar S; Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong SAR, China.
  • Yuen KY; Infection Control Team, Queen Mary Hospital, Hong Kong West Cluster, Hong Kong SAR, China.
  • Hung IF; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, The University of Hong Kong, Hong Kong SAR, China.
  • Chan KH; Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong SAR, China.
  • To KK; Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Nat Commun ; 13(1): 3618, 2022 06 24.
Article Dans Anglais | MEDLINE | ID: covidwho-1908176
ABSTRACT
Monitoring population protective immunity against SARS-CoV-2 variants is critical for risk assessment. We hypothesize that Hong Kong's explosive Omicron BA.2 outbreak in early 2022 could be explained by low herd immunity. Our seroprevalence study using sera collected from January to December 2021 shows a very low prevalence of neutralizing antibodies (NAb) against ancestral virus among older adults. The age group-specific prevalence of NAb generally correlates with the vaccination uptake rate, but older adults have a much lower NAb seropositive rate than vaccination uptake rate. For all age groups, the seroprevalence of NAb against Omicron variant is much lower than that against the ancestral virus. Our study suggests that this BA.2 outbreak and the exceptionally high case-fatality rate in the ≥80 year-old age group (9.2%) could be attributed to the lack of protective immunity in the population, especially among the vulnerable older adults, and that ongoing sero-surveillance is essential.
Sujets)

Texte intégral: Disponible Collection: Bases de données internationales Base de données: MEDLINE Sujet Principal: SARS-CoV-2 / COVID-19 Type d'étude: Études expérimentales / Étude observationnelle / Étude pronostique / Essai contrôlé randomisé Les sujets: Vaccins / Variantes Limites du sujet: Adulte très âgé / Humains Pays comme sujet: Asie langue: Anglais Revue: Nat Commun Thème du journal: Biologie / Science Année: 2022 Type de document: Article Pays d'affiliation: S41467-022-31395-0

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS


Texte intégral: Disponible Collection: Bases de données internationales Base de données: MEDLINE Sujet Principal: SARS-CoV-2 / COVID-19 Type d'étude: Études expérimentales / Étude observationnelle / Étude pronostique / Essai contrôlé randomisé Les sujets: Vaccins / Variantes Limites du sujet: Adulte très âgé / Humains Pays comme sujet: Asie langue: Anglais Revue: Nat Commun Thème du journal: Biologie / Science Année: 2022 Type de document: Article Pays d'affiliation: S41467-022-31395-0